leuprolide acetate injection solution — CareFirst (Caremark)

Initial criteria

• Treatment of prostate cancer

Reauthorization criteria

• Member is experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL)
• Member has not experienced an unacceptable toxicity

Approval duration

12 months